Skip to content
MarketScale
‹ Back to IndustriesHealthcare

NIH Puts New Clinical Trial Guidelines Into Effect

Researchers requesting funding for clinical trials must determine if their research meets new criteria set by new NIH guidelines. The new guidelines breaks from the traditional understanding to also  include both basic biomedical research and basic social and behavioral research. The switch has caused somewhat of a controversy, with some researchers claiming that the guidelines…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Researchers requesting funding for clinical trials must determine if their research meets new criteria set by new NIH guidelines. The new guidelines breaks from the traditional understanding to also include both basic biomedical research and basic social and behavioral research.

The switch has caused somewhat of a controversy, with some researchers claiming that the guidelines are too broad, and the new policies will increase researcher burdens. In September, more than 3500 scientists signed an open letter requesting NIH to delay the policy. Researchers conducting trials are now required to register and report results on ClinicalTrials.gov, but, if researchers impacted by the change do not select a funding opportunity that supports clinical trials when they apply to NIH, their grant is subjected to be rejected without a review.

Though some clarification from NIH in recent months has quelled many of the concerns expressed, some researchers have lingering doubts. “There’s still a problem, but the problem is less dire than the original set of concerns that we had,” says cognitive psychologist Jeremy Wolfe of the Harvard University.[1]

The guidelines go into effect on January 25th.

[1]

http://www.sciencemag.org/news/2018/01/nih-s-new-clinical-trial-policy-kicks-despite-concerns-basic-behavioral-researchers

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Healthcare digital transformation stalls when teams stay disconnected

Healthcare digital transformation stalls when teams stay disconnected

Despite over 70% of healthcare executives prioritizing digital transformation, fragmented communication and information silos are hindering progress. Effective teamwork and integration are critical for achieving these goals. Bridging these gaps could enhance results in the healthcare industry's digital initiatives.

  • 01Over 70% of healthcare executives prioritize digital transformation.
  • 02Fragmented communication and information silos limit progress.
  • 03Effective integration is crucial for successful digital initiatives.

Jul 15, 2026

The Future of Healthcare Is Already Here: Dr. Geoffrey Rutledge on Virtual Care, AI, and Access

The Future of Healthcare Is Already Here: Dr. Geoffrey Rutledge on Virtual Care, AI, and Access

The article discusses the advancements in healthcare with a focus on virtual care, AI, and access, featuring insights from Dr. Geoffrey Rutledge. It explores how these technologies are shaping the future of healthcare delivery. The conversation touches upon the impact on patient care and the potential for improved healthcare accessibility.

  • 01Virtual care and AI are transforming healthcare.
  • 02These technologies enhance patient accessibility and care.
  • 03Healthcare delivery is continuously evolving with new innovations.

Jul 14, 2026

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512